Interspecies Scaling: Predicting Volumes, Mean Residence Time and Elimination Half‐life. * Some Suggestions

Extrapolation of animal data to assess pharmacokinetic parameters in man is an important tool in drug development. Clearance, volume of distribution and elimination half‐life are the three most frequently extrapolated pharmacokinetic parameters. Extensive work has been done to improve the predictive performance of allometric scaling for clearance. In general there is good correlation between body weight and volume, hence volume in man can be predicted with reasonable accuracy from animal data. Besides the volume of distribution in the central compartment (Vc), two other volume terms, the volume of distribution by area (Vβ) and the volume of distribution at steady state (Vdss), are also extrapolated from animals to man. This report compares the predictive performance of allometric scaling for Vc, Vβ and Vdss in man from animal data.

[1]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[2]  J. Aramayona,et al.  Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. , 1996, American journal of veterinary research.

[3]  W. Löscher.  Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. , 1978, The Journal of pharmacology and experimental therapeutics.

[4]  R. Wise,et al.  Pharmacokinetics of intravenously administered ciprofloxacin , 1984, Antimicrobial Agents and Chemotherapy.

[5]  G. Drusano,et al.  Dose ranging study and constant infusion evaluation of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.

[6]  M Widman,et al.  Disposition of remoxipride in different species. Species differences in metabolism. , 1993, Arzneimittel-Forschung.

[7]  R C Chou,et al.  Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. , 1997, Journal of pharmaceutical sciences.

[8]  John F. Young,et al.  Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse. , 1984, Drug metabolism reviews.

[9]  M. Andersen,et al.  Interspecies Scaling in Pharmacokinetics , 1991 .

[10]  M. Hammarlund-Udenaes,et al.  Remoxipride: pharmacokinetics and effect on plasma prolactin. , 1991, British journal of clinical pharmacology.

[11]  G. S. Duthu.  Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. , 1985, Journal of pharmaceutical sciences.

[12]  M. Williams,et al.  Interspecies comparison of acivicin pharmacokinetics. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[13]  R. Sawchuk,et al.  The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit. , 1985, Drug Metabolism And Disposition.

[14]  T. Lavé,et al.  Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. , 1995, Journal of pharmaceutical sciences.

[15]  H Boxenbaum,et al.  Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. , 1984, Drug metabolism reviews.

[16]  M. Mayersohn,et al.  Comparative Pharmacokinetics and Interspecies Scaling of Amphotericin B in Several Mammalian Species , 1997, The Journal of pharmacy and pharmacology.

[17]  W. Calder,et al.  Body Size, Physiological Time, and Longevity of Homeothermic Animals , 1981, The Quarterly Review of Biology.

[18]  M Bonati,et al.  Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[19]  M. Sáez,et al.  Disposition of ciprofloxacin following intravenous administration in dogs. , 1994, Journal of veterinary pharmacology and therapeutics.

[20]  I Mahmood,et al.  Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. , 1996, Journal of pharmaceutical sciences.

[21]  K. Bachmann.  Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species , 1989, Journal of applied toxicology : JAT.

[22]  R. Schinazi,et al.  Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species. , 1990, Journal of pharmacobio-dynamics.

[23]  W. Löscher,et al.  Pharmacokinetics of ethosuximide in the dog. , 1978, Archives internationales de pharmacodynamie et de therapie.

[24]  T. Starzl,et al.  CYCLOSPORINE METABOLISM AND PHARMACOKINETICS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION IN THE DOG1 , 1986, Transplantation.

[25]  T. Lavé,et al.  Animal Pharmacokinetics and Interspecies Scaling from Animals to Man of Lamifiban, a New Platelet Aggregation Inhibitor , 1996, The Journal of pharmacy and pharmacology.

[26]  D. Jaeck,et al.  Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[27]  Leon Shargel,et al.  Applied biopharmaceutics and pharmacokinetics , 1980 .

[28]  J. Balian,et al.  Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  L. Whitfield,et al.  Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. , 1990, Cancer research.